Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

What is next, and who is running it?

Programs by company or class, across phase, filing, approval, and a stop.

A black mark is a readout. A yellow mark is another company date. A circle is an approval or an FDA action date the source names. A hollow mark is a registry primary completion date.

Phase 1 on
ClassNone selected

Phase 1 included.

Clear filters

23 of 23 programs on this matrix

Phase 1Phase 2Phase 3FiledApprovedDiscontinued
B7-H4-directed ADC2 programs
CXCR1/2 inhibitor1 program
SX-682 + Docetaxel

Registry, Oct 2036

Dosing n/r

CXCR1/2 inhibitor · National Cancer Institute

EGFR x MET bispecific antibody1 program
Amivantamab

Phase 2

intravenous

EGFR x MET bispecific antibody · Trisha Wise-Draper (investigator)

gamma secretase inhibitor1 program
HDAC inhibitor1 program
HG146

Registry, Dec 31, 2028

Dosing n/r

HDAC inhibitor · HitGen

KIT-directed ADC1 program
NN3201

Registry, Aug 30, 2027

Dosing n/r

KIT-directed ADC · Novelty Nobility

MDM2 inhibitor1 program
multi-kinase TKI1 program
multi-kinase TKI with chemotherapy1 program
MYB mRNA degrader1 program
REM-422

ENA 2026 late-breaking oral 5LBA (updated Phase 1), Nov 19, 2026

once daily, oral, once daily

MYB mRNA degrader · Remix Therapeutics (merging with Passage Bio)

MYB splicing modulator1 program
RGT-61159

Phase 3 start (company plan), Q1 2027

once daily, oral, once daily

MYB splicing modulator · Rgenta Therapeutics

Nectin-4-directed ADC1 program
Enfortumab Vedotin

Registry, Mar 2027

Dosing n/r

Nectin-4-directed ADC · Memorial Sloan Kettering

pan-NOTCH transcription inhibitor1 program
CB-103

Registry, Jun 2027

oral (not re-verified)

pan-NOTCH transcription inhibitor · Cellestia Biotech

PD-1 x VEGF bispecific1 program
Ivonescimab

Registry, Jul 2027

Dosing n/r

PD-1 x VEGF bispecific · Dana-Farber Cancer Institute

PSMA radioligand1 program
TrkA inhibitor1 program
VMD-928

Registry, Dec 2027

Dosing n/r

TrkA inhibitor · VM Oncology

TROP2-directed ADC1 program
VEGFR multi-kinase TKI1 program
Lenvatinib (off Label)

Registry, Dec 2026

once daily, oral

VEGFR multi-kinase TKI · Eisai (investigator studies)

VEGFR TKI1 program
VEGFR/MET/TAM TKI1 program
VEGFR2 TKI2 programs
Apatinib

Phase 2

Dosing n/r

VEGFR2 TKI · Shanghai Ninth People's Hospital

Rivoceranib

Trials stopped

once daily, oral

Registry records are terminated or withdrawn.

VEGFR2 TKI · Elevar Therapeutics